Does Rallies show Form 4 insider transactions for GLUE?

Yes. Rallies tracks GLUE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is GLUE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GLUE. It does not provide personalized investment advice.

GLUE (Monte Rosa Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Monte Rosa Therapeutics, Inc. Common Stock (GLUE) is a publicly traded Healthcare sector company. As of May 21, 2026, GLUE trades at $18.56 with a market cap of $1.52B and a P/E ratio of 0.00. GLUE moved +6.09% today. Year to date, GLUE is +29.51%; over the trailing twelve months it is +348.32%. Its 52-week range spans $3.50 to $25.77. Analyst consensus is strong buy with an average price target of $32.80. Rallies surfaces GLUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading GLUE stock inside the company?

Recent GLUE insider activity includes Warmuth Markus sold 5.47K, Warmuth Markus sold 8.00K, Nickson Philip sold 5.84K, Dunn Edmund sold 139, and Warmuth Markus sold 5.47K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

GLUE Key Metrics

Key financial metrics for GLUE
Metric	Value
Price	$18.56
Market Cap	$1.52B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$25.77
52-Week Low	$3.50
Volume	1.93K
Avg Volume	0
Revenue (TTM)	$75.62M
Net Income	$-72.70M
Gross Margin	0.00%

Recent GLUE Insider Trades

Warmuth Markus sold 5.47K (~$103.45K) on May 1, 2026.
Warmuth Markus sold 8.00K (~$141.12K) on Apr 14, 2026.
Nickson Philip sold 5.84K (~$103.41K) on Apr 9, 2026.
Dunn Edmund sold 139 (~$2.50K) on Mar 4, 2026.
Warmuth Markus sold 5.47K (~$97.97K) on Mar 2, 2026.

Latest GLUE News

Monte Rosa Therapeutics Posts $0.45 Q1 Loss, Misses Revenue Estimates — May 7, 2026
Monte Rosa Therapeutics Cuts CRP by 85%, Eyes H2 2026 Phase 2 Trials — May 7, 2026
Monte Rosa Secures J&J Supply for Phase 2 MRT-2359/Apalutamide mCRPC Trial — Mar 16, 2026
Monte Rosa Reports 100% PSA Response in AR-Mutant mCRPC; Phase 2 Set for Q3 2026 — Feb 24, 2026
Monte Rosa Therapeutics Prices 11.125M Shares at $24, Raises $300M in Public Offering — Jan 9, 2026

GLUE Analyst Consensus

7 analysts cover GLUE: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.80.

Common questions about GLUE

Who is trading GLUE stock inside the company?: Recent GLUE insider activity includes Warmuth Markus sold 5.47K, Warmuth Markus sold 8.00K, Nickson Philip sold 5.84K, Dunn Edmund sold 139, and Warmuth Markus sold 5.47K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for GLUE?: Yes. Rallies tracks GLUE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is GLUE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GLUE. It does not provide personalized investment advice.